Research programme: oral E-selectin inhibitors - GlycoMimetics
Latest Information Update: 25 Apr 2023
At a glance
- Originator GlycoMimetics
- Class
- Mechanism of Action E-selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Cardiovascular disorders; Inflammation
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Cancer in USA (PO)
- 25 Apr 2023 Discontinued - Preclinical for Cardiovascular disorders in USA (PO)
- 25 Apr 2023 Discontinued - Preclinical for Inflammation in USA (PO)